USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
NEUROP, INC.
Address:
58 Edgewood Road
ATLANTA, GA
Phone:
N/A
URL:
N/A
EIN:
30441817
DUNS:
148559987
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,217,321.00 4
SBIR Phase II $4,078,584.00 2
STTR Phase I $144,137.00 1

Award List:

In vivo proof of concept:pH-dependent neuroprotection

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Neurodegeneration accompanying stroke and certain types of seizure is a significant problem that has been refractory to treatment despite intensive investigation in both the public and private sector. Neuronal degeneration in animal models can be substantially… More

pH-Sensitive Glutamate Receptor Inhibitors: Clinical Candidate Selection

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$1,403,583.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Ischemic injury of the brain is a major cause of death and morbidity, and often causes long term disability. NMDA receptor (NMDAR) blockers, particularly targeting the NR2B-subunit are neuroprotective in ischemic disease animal models. Unfortunately, most NMDAR… More

Neuroprotection of pH Sensitive NMDAR Antagonists in Cardiopulmonary Bypass Surge

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$125,788.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Heart operations involving the use of cardiopulmonary bypass (CPB) are among the most common surgical procedures in the world, with over 500,000 performed in the U.S. alone in 2000. Such procedures carry a significant r isk of cerebral injury including death,… More

Evaluation of pH Dependent Neuroprotectants in SAH Model

Award Year / Program / Phase:
2008 / STTR / Phase I
Award Amount:
$144,137.00
Agency:
HHS
Principal Investigator:
Research Institution:
N/A
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The goal of this STTR project is to determine if NeurOp's pH-sensitive NMDAR antagonists improve functional recovery and reduce neuronal injury in a validated murine model of vasospasm following subarachnoid hemorrhage (SAH). Subarachnoid hemorrhage (SAH)… More

Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$299,541.00
Agency:
HHS
Principal Investigator:
George W. Koszalka – 404-941-2360
Abstract:
DESCRIPTION (provided by applicant): Cerebral ischemia is a major cause of death and long-term disability, with high accompanying social and medical costs. Approximately 795,000 Americans suffer a stroke each year at an estimated annual cost of 73.7B (American Heart Association. Heart Disease and… More

Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$2,675,001.00
Agency:
HHS
Principal Investigator:
George W. Koszalka – 404-941-2360
Abstract:
DESCRIPTION (provided by applicant): Cerebral ischemia is a major cause of death and long-term disability, with high accompanying social and medical costs. Approximately 795,000 Americans suffer a stroke each year at an estimated annual cost of 73.7B (American Heart Association. Heart Disease and… More

Optimization of Novel NR2C and NR2D subunit-selective NMDA receptor potentiators

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$691,992.00
Agency:
HHS
Principal Investigator:
Scott J. Myers – 404-941-2350
Abstract:
DESCRIPTION (provided by applicant): Schizophrenia is a chronic neurological disorder that affects approximately 1% of the world population and causes gt 60 billion dollars of direct and indirect societal costs in the US alone (Wu et al., 2005). Current therapies to treat this disorder have been… More